On August 3, 2023 GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE platform, reported that Dr. Jeffrey Miller, MD, GT Biopharma’s Consulting Chief Medical Officer and Consulting Chief Scientific Officer, will participate in a fireside chat and the Keynote Session: KOL roundtable discussion at H.C. Wainwright’s Immune Cell Engager Conference taking place August 17, 2023 (Press release, GT Biopharma, AUG 3, 2023, View Source [SID1234633748]). Company management will also be participating in 1×1 meetings during the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright Immune Cell Engager Conference – August 17, 2023
Title: GT Biopharma (GTBP) Company Presentation
Date: Thursday, August 17, 2023
Time: 3:30 pm ET
Presenter: Dr. Jeffrey Miller, MD, Consulting CMO & CSO, GT Biopharma
Webcast Link: Register HERE

Title: Keynote Session: KOL Roundtable Discussion
Date: Thursday, August 17, 2023
Time: 12:00-1:00 pm ET
Participant: Dr. Jeffrey Miller, MD, Deputy Director, Masonic Cancer Center, Co-Leader Immunology Program & Roger L. & Lynn C. Headrick Chair, Cancer Therapeutics, University of Minnesota
If you are interested in arranging a 1×1 meeting request with management, please contact your H.C. Wainwright representative. A replay of the company presentation will be available on the Presentations page of the GT Biopharma website.